2025.8 Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Akeso, Inc. (the "Company"). This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in a ...

AGENDA 01. HIGHLIGHTS 04.ESG 02. FINANCIAL REVIEW 03.BUSINESS REVIEW 05. LAND BANK 06. OUTLOOK 07.APPENDIX 三亚海棠湾悦府 西安万象城 Xi'an Mixc P A R T PART ONE Results Highlights Strengthening Momentum of the Second Growth Curve for Stable Performance and Returns Revenue +19.9% YoY Recurring Income +2.5% YoY RMB 94.9bn RMB 20.6bn Weighted Average Funding Cost 2.79% -32bps from FY24 Attributable Net Profit +16.2% YoY Recurring Core Net Profit RMB 11.9 +9.6% YoY bn RMB 6.0bn Net Gearing Ratio 39.2% Core Net Profit -6.6% ...

Financial Performance - The company's revenue reached RMB 131867 million, a 25% year-over-year increase[11] - Gross profit increased to RMB 21510 million, representing a 28% increase[11] - Net profit attributable to shareholders was RMB 2077 million, a decrease of 203%[11] - Operating cash flow significantly improved, reaching RMB 1531 million, a 2501% increase compared to the previous year[11] Business Segments - Pharmaceutical manufacturing business revenue was RMB 2481 billion, up 43% year-over-year, while segment gross profit margin decreased by 08 percentage points to 593%[19, 20] - Commercial business revenue increased by 23% to RMB 108330 million[62] - The medical device business achieved revenue of RMB 18 billion, an 8% year-over-year increase[70] Strategic Initiatives - The company completed the acquisitions of Nigale and Tasly to expand into the medical device sector and solidify its position in the TCM industry[22, 24] - The company is committed to innovative R&D, with 476 total projects under research and development, including 178 new drugs[36] - The company is strengthening international expansion, with overseas API revenue reaching RMB 360 million in the first half of the year[53, 58]

Financial Performance - Clean Energy revenue significantly increased by 222% YoY[9], reaching RMB 9626 million[9] - Basic Earnings Per Share Increased to RMB 0278 per share[12] - Net Asset Value (NAV) per Share increased to RMB 6540 per share[14] - Annualised ROE Increased by 1pp to 97% YoY[15] - Overall Cash Conversion Cycle (CCC) was 25 days[18], optimised by 11 days YoY[18] Segment Results and Orders - Clean energy reportable segment profit increased significantly by 295% YoY[31], reaching RMB 560 million[31] - Newly signed orders for clean energy totaled RMB 897 billion[40], with offshore clean energy accounting for RMB 324 billion[40] - Backlog orders of clean energy stood at RMB 2520 billion[43], up 10% YoY[43] - Newly signed orders for liquid food reached RMB 690 million[40], a 62% QoQ increase from Q1 to Q2 in 2Q25[40] Business Highlights and Outlook - China's LNG imports declined by 206% YoY[59] to 3011 million tons[59] - The global tank container fleet reached 882023 units[147], representing an increase of 396% compared with 2024[147] - CLPT completed a new round of private placement in July 2025[154], raising RMB 110 million[154] and adding 19079434 new shares[154]

2025 Interim Results Presentation August 2025 China Everbright Environment Group Limited Forward-looking Statement This presentation may contain forward-looking statements. Any such forward-looking statements are based on a number of assumptions about the operations of China Everbright Environment (Group) Limited ("Everbright Environment" or the "Company", together with its subsidiaries, collectively the "Group") and factors beyond the Company's control and are subject to significant risks and uncertainties ...

Industry Review Business Review Financial Results Global Wind Power Market Onshore Offshore 2025 Interim Results 88.4 72.5 68.8 105.7 109.0 6.9 21.1 8.8 10.9 8.0 95.3 93.6 77.6 116.6 117.0 2020 2021 2022 2023 2024 Global Annual New Installation (GW) Wind power has become the most economical renewable energy source（USD/KWh） 0.087 0.06 0.057 0.043 0.092 0.079 0.034 0.086 0.055 0.044 0.417 0.402 0.208 0.113 Bioenergy Geothermal Hydropower Solar PV Concentrated solar power Offshore wind Onshore wind global LCOE ...

West China Cement 1 Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of West China Cement Limited (the "Issuer" together with its subsidiaries, the "Group") for use in presentations by the Issuer at investor meetings for information purposes only and does not constitute a recommendation, invitation or offer to acquire, pur ...

Financial Performance - Henlius achieved a revenue of RMB 2.82 billion in 2025 H1, representing a 2.7% year-over-year growth[5, 207, 212] - Product sales reached RMB 2.56 billion in 2025 H1, a 3.1% year-over-year increase[6, 207, 212] - The company's net profit was RMB 386 million, with a net profit margin of 13.8%[5, 6] - Net operating cash inflow reached RMB 770 million, showing a 207% year-over-year growth[6] Business Development & Out-licensing - BD contract cash inflow exceeded RMB 1 billion in 2025 H1, a 280% year-over-year growth[6] - Out-licensing deals include HLX13 (Ipilimumab) to Sandoz for up to USD 300 million, HLX15 (daratumumab) to Dr Reddy's for up to USD 131.6 million, and HANSIZHUANG (serplulimab) to Lotus in South Korea for up to USD 112 million[6, 48] - Recent major out-licensing products contributed cash inflow of approximately RMB 670 million in 1H25[47] Key Products Performance - HANSIZHUANG sales reached RMB 0.6 billion in 2025 H1[6] - HANQUYOU global revenue in 1H2025 was RMB 1.44 billion[146] - HANBEITAI revenue in 1H2025 was RMB 116 million[176] - HANNAIJIA revenue in 1H2025 was RMB 97 million[158] - HANLIKANG revenue in 1H2025 was RMB 274 million[186] - HANDAYUAN revenue in 1H2025 was RMB 27 million[186]

Financial Performance - The company's revenue decreased by 18.5% from RMB 16,284 million in 2024H1 to RMB 13,273 million in 2025H1[35] - Gross profit decreased by 25.3% from RMB 11,655 million in 2024H1 to RMB 8,710 million in 2025H1[35] - Gross profit margin decreased by 6.0 percentage points from 71.6% in 2024H1 to 65.6% in 2025H1[35] - Reported profit attributable to shareholders of the Company decreased by 15.6% from RMB 3,020 million in 2024H1 to RMB 2,548 million in 2025H1[35] - Underlying profit attributable to shareholders of the Company decreased by 27.9% from RMB 3,217 million in 2024H1 to RMB 2,320 million in 2025H1[35] - Revenue from finished drugs decreased by 24.4% from RMB 13,549 million in 2024H1 to RMB 10,248 million in 2025H1[36] - Revenue from bulk vitamin C increased by 21.6% from RMB 984 million in 2024H1 to RMB 1,196 million in 2025H1[36] - Revenue from nervous system therapeutics decreased by 28.3% from RMB 5,236 million in 2024H1 to RMB 3,755 million in 2025H1[37] - Revenue from oncology therapeutics decreased significantly by 60.8% from RMB 2,683 million in 2024H1 to RMB 1,051 million in 2025H1[37] R&D and Pipeline - The company has 5 R&D centers located in China & the U S [6,99] - The company has approximately 200 innovative drugs and new formulations [6,99] - R&D expenses increased by 5.5% from RMB 2,542 million in 2024H1 to RMB 2,683 million in 2025H1[35] Business Development - The company has license-out agreements including a potential milestone payment of $105 billion for GLP-1, $522 billion for ROR1 ADC, $1955 billion for Irinotecan Liposome Injection, and $1225 billion for strategic collaboration [116]

Financial Performance - Total revenues decreased by 3.6%, from RMB 4041.8 million in 2024 1H to RMB 3894.5 million in 2025 1H[28] - Aviation information technology services revenue increased by 2.1%, from RMB 2265.0 million in 2024 1H to RMB 2313.4 million in 2025 1H[33] - Settlement and clearing services revenue increased by 12.4%, from RMB 278.0 million in 2024 1H to RMB 312.5 million in 2025 1H[33] - System integration services revenue decreased significantly by 38.5%, from RMB 679.8 million in 2024 1H to RMB 418.4 million in 2025 1H[33] - Income from technical support and products increased by 30.4%, from RMB 295.3 million in 2024 1H to RMB 385.0 million in 2025 1H[33] - Other income decreased by 10.2%, from RMB 307.2 million in 2024 1H to RMB 275.7 million in 2025 1H[33] - Total operating expenses decreased by 4.2%, from RMB 2535.3 million in 2024 1H to RMB 2427.9 million in 2025 1H[41] Operational Data - Total volume processed by the systems increased by 5.31% compared to 2024 1H and increased by 9.91% compared to 2019 1H[12] - The processing volume of China Airlines' system handled by China Aviation Information Corporation is about 360 million people, a year-on-year increase of 5.5% and a year-on-year increase of 12.5% compared to the same period in 2019[17] Future Investments - The company's capital expenditure commitment amounted to approximately RMB 1518.7 million as of June 30, 2025[47] - The relevant budget for Beijing Shunyi Park Phase II is approximately RMB 938.0 million, and the total expenditures for Shunyi Phase II Project not exceeding RMB 1032.0 million[51]